We found that TERT mutations were associated with poor prognosis, while PD-L1, TMB, and TP53 were associated with response to immune checkpoint blockade in patients with advanced HCC treated with targeted and immunotherapy. The gene discussed is CD274; the disease is hepatocellular carcinoma.